[1] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组.中国缺血性卒中和短暂性脑缺血发作二级预防指南2022[J].中华神经科杂志,2022,55(10):1071-1110. [2] HUI C,TADI P,KHAN S M,et al.Ischemic stroke[J].Florida:StatPearls,2024. [3] PARADOWSKI B,MACIEJAK A.TOAST classification of subtypes of ischaemic stroke:diagnostic and therapeutic procedures in stroke:A four-year observation[J].Cerebrovasc Dis,2005,20(5):319-324. [4] ROJSANGA W,SAWANYAWISUTH K,CHOTMONGKOL V,et al.Clinical risk factors predictive of thrombotic stroke with large cerebral infarction[J].Neurol Int,2019,11(2):7941. [5] 谷文龙,黄玉宇,王红武,等.代谢综合征与心血管疾病和痴呆的关系[J].广州医药,2017,48(4):51-55,59. [6] BOEHME A K,ESENWA C,ELKIND M S V.Stroke risk factors,genetics,and prevention[J].Circ Res,2017,120(3):472-495. [7] LANFRANCO M F,SEPULVEDA J,KOPETSKY G,et al.Expression and secretion of apoE isoforms in astrocytes and microglia during inflammation[J].Glia,2021,69(6):1478-1493. [8] WINDHAM I A,COHEN S.The cell biology of APOE in the brain[J].Trends Cell Biol,2024,34(4):338-348. [9] KUMAR A,KUMAR P,PRASAD M,et al.Association between apolipoprotein epsilon4 gene polymorphism and risk of ischemic stroke:A meta-analysis[J].Ann Neurosci,2016,23(2):113-121. [10] YE B S,KIM H J,YOON C,et al.P2-071:Effects of APOE-ε4 on lacunar infarcts,white matter lesions and brain amyloid:A study among people with subcortical vascular cognitive impairment[J].Alzheimers Dement,2013,9(4S_Part_9):369-370. [11] QUAN M,LV H,LIU Z,et al.MST1 suppresses disturbed flow induced atherosclerosis[J].Circ Res,2022,131(9):748-764. [12] ZHANG H,ZHAO X,WANG C,et al.A preliminary study of the association between apolipoprotein E promoter methylation and atherosclerotic cerebral infarction[J].J Stroke Cerebrovasc Dis,2019,28(4):1056-1061. [13] NELSON K,FUSTER V,RIDKER P M.Low-dose colchicine for secondary prevention of coronary artery disease:JACC review topic of the week[J].J Am Coll Cardiol,2023,82(7):648-660. [14] XU D,XIE L,CHENG C,et al.Triglyceride-rich lipoproteins and cardiovascular diseases[J].Front Endocrinol,2024(15):1409653. [15] SACKS F M,FURTADO J D,JENSEN M K.Protein-based HDL subspecies:Rationale and association with cardiovascular disease,diabetes,stroke,and dementia[J].Biochim Biophys Acta Mol Cell Biol Lipids,2022,1867(9):159182. [16] MARAIS A D.Apolipoprotein E in lipoprotein metabolism,health and cardiovascular disease[J].Pathology,2019,51(2):165-176. [17] RASMUSSEN K L,TYBJAERG-HANSEN A,NORDESTGAARD B G,et al.APOE and dementia - resequencing and genotyping in 105,597 individuals[J].Alzheimers Dement,2020,16(12):1624-1637. [18] DAS S,KAUL S,JYOTHY A,et al.Association of APOE(E2,E3 and E4)gene variants and lipid levels in ischemic stroke,its subtypes and hemorrhagic stroke in a South Indian population[J].Neurosci Lett,2016(628):136-141. [19] ZHAO T,ZHONG T,ZHANG M,et al.Alzheimer's disease:Causal effect between obesity and APOE gene polymorphisms[J].Int J Mol Sci,2023,24(17):13531. [20] WANG Q Y,WANG W J,WU L,et al.Meta-analysis of APOE ε2/ε3/ε4 polymorphism and cerebral infarction[J].J Neural Transm,2013,120(10):1479-1489. [21] YAN H Q,YUAN Y,ZHANG P,et al.Association of the ApoE gene polymorphism and dietary factors with cerebral infarction and circulating lipid concentrations[J].Genet Mol Res,2015,14(1):665-670. [22] ZHONG Z,WU H,YE M,et al.Association of APOE gene polymorphisms with cerebral infarction in the Chinese population[J].Med Sci Monit,2018(24):1171-1177. [23] KHALIL Y A,RABES J P,BOILEAU C,et al.APOE gene variants in primary dyslipidemia[J].Atherosclerosis,2021(328):11-22. [24] MIAO G,ZHUO D,HAN X,et al.From degenerative disease to malignant tumors:Insight to the function of ApoE[J].Biomed Pharmacother,2023(158):114127. [25] CHENG Y W,LIAO Y C,CHEN C H,et al.Contribution of the APOE genotype to cognitive impairment in individuals with NOTCH3 cysteine-altering variants[J].J Am Heart Assoc,2023,12(22):e032689. [26] DAVIDSON Y,GIBBONS L,PURANDARE N,et al.Apolipoprotein E epsilon4 allele frequency in vascular dementia[J].Dement Geriatr Cogn Disord,2006,22(1):15-19. [27] KLAGES J D,FISK J D,ROCKWOOD K.APOE genotype,vascular risk factors,memory test performance and the five-year risk of vascular cognitive impairment or Alzheimer's disease[J].Dement Geriatr Cogn Disord,2005,20(5):292-297. [28] NOGUCHI S,MURAKAMI K,YAMADA N.Apolipoprotein E genotype and Alzheimer's disease[J].Lancet,1993,342(8873):737. [29] MONTAGNE A,NATION D A,SAGARE A P,et al.APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline[J].Nature,2020,581(7806):71-76. [30] 罗伏钢,陈梅芳,章隆,等.ApoE基因多态性与脑梗死后血管性痴呆的关联性研究[J].中华全科医学,2018,16(6):874-877. [31] STOCKER H,PERNA L,WEIGL K,et al.Prediction of clinical diagnosis of Alzheimer's disease,vascular,mixed,and all-cause dementia by a polygenic risk score and APOE status in a community-based cohortprospectively followed over 17 years[J].Mol Psychiatry,2021,26(10):5812-5822. [32] XIONG M,JIANG H,SERRANO J R,et al.APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function[J].Sci Transl Med,2021,13(581):eabd7522. [33] NORDESTGAARD L T,CHRISTOFFERSEN M,FRIKKE-SCHMIDT R.Shared risk factors between dementia and atherosclerotic cardiovascular disease[J].Int J Mol Sci,2022,23(17):9777. |